80.42 -0.27 (-0.33%)
After hours: 5:14PM EST
|Bid||80.41 x 300|
|Ask||80.98 x 300|
|Day's Range||80.36 - 81.93|
|52 Week Range||63.76 - 89.54|
|PE Ratio (TTM)||22.99|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||2.28 (2.83%)|
|1y Target Est||88.77|
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to break down the latest in the markets.
LONDON, UK / ACCESSWIRE / February 21, 2018 / Active-Investors.com has just released a free research report on Gilead Sciences, Inc. (NASDAQ: GILD ) ("Gilead"). If you want access to this report ...
Merck fell after a judge tossed a record $2.54 billion verdict it had won against Gilead Sciences over a hepatitis treatment.
Merck & Co. Inc. shares dipped 1.6% in morning trade Tuesday after the company lost a patent case to Gilead Sciences Inc. . Gilead shares rose 0.4% in morning trade. The case, which involves alleged patent ...
Merck & Co. fell after a federal judge tossed a record $2.54 billion verdict it had won against Gilead Sciences Inc. over a hepatitis treatment.
Novartis: What Are the Major Growth Drivers for 2018? On October 31, 2017, Novartis (NVS) announced the submission of a supplemental biologics license application (or sBLA) to the FDA. The sBLA seeks approval for Kymriah as a treatment option for adult patients with relapsed/refractory diffuse large B-cell lymphoma (or r/r DLBCL).
Novartis: What Are the Major Growth Drivers for 2018? On August 30, 2017, Novartis’ (NVS) CAR T-cell therapy, Kymriah, secured approval from the FDA as a treatment option for patients below 25 years of age who have B-cell precursor acute lymphoblastic leukemia (or ALL). This drug, which is developed by the company in collaboration with the University of Pennsylvania, is indicated only in cases when ALL is refractory or has relapsed a second time or more.
A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck's patent was invalid. Gilead in a statement on Saturday said it always believed the patent was invalid and was pleased the judge confirmed that opinion.
The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck's patent was invalid. Gilead did not immediately respond to a request for comment on Saturday. The December 2016 verdict followed a trial in which jurors found that Merck's patent on hepatitis C treatments, which it acquired in 2014 when it bought Idenix Pharmaceuticals, was valid.
Investors with a long-term horizong may find it valuable to assess Gilead Sciences Inc’s (NASDAQ:GILD) earnings trend over time and against its industry benchmark as opposed to simply looking atRead More...
This year could be big for biotech mergers after Celgene and Sanofi, in a few days, spent $25 billion for three companies.
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
“We expect to invest over $5 billion in construction and grow this second headquarters to include as many as 50,000 high-paying jobs – it will be a full equal to our current campus in Seattle,” Amazon (AMZN) declares. “In addition to Amazon’s direct hiring and investment, construction and ongoing operation of Amazon HQ2 is expected to create tens of thousands of additional jobs and tens of billions of dollars in additional investment in the surrounding community.” No wonder the finalists want Amazon to come. If Amazon truly wants “to find a city that is excited to work with us,” perhaps it should give special attention to finalist Nashville, Tennessee’s capital, considering that the state treasury lifted its Amazon investment by 33% in the fourth quarter.
For 4Q17, Novartis’s (NVS) Entresto reported sales of $185 million around the world, which represents a YoY (year-over-year) rise of 172% on a reported basis and a 164% YoY rise on a CC (constant currency) basis. Novartis reported Entresto sales of ~$507 million for fiscal 2017, which represents a YoY rise of ~198% on a reported basis. Novartis has now launched Entresto in almost 60 countries worldwide, with its latest launch just completed in China.
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / U.S. markets managed to finish in the green on Friday, despite concerns of rising interest rates and inflationary pressure. The Dow Jones Industrial Average ...